The Food and Drug Administration's announcement that it will hire the government's top scientific review agency to address concerns about how the FDA handles safety problems may result in higher scrutiny and drug development costs for biotechnology companies, according to industry insiders...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99